Key Stats for IDEXX Laboratories Stock
- 52-Week Range: $428 to $770
- Current Price: $561
- Street Mean Target: $733
- Street High Target: $823
- TIKR Model Target (Dec. 2030): $919
What Happened?
IDEXX Laboratories (IDXX), the global leader in veterinary diagnostics and software, closed Q4 2025 with 14% reported revenue growth to $1.09 billion — and IDEXX laboratories stock has yet to reflect the installed-base flywheel that record quarter set in motion.
The quarter’s defining number was 6,567 premium instrument placements, up 42% from the prior year, including over 1,900 inVue Dx analyzers, IDEXX’s AI-powered point-of-care cytology platform that automates cell analysis previously requiring external lab interpretation.
For the full year, inVue Dx contributed over $75 million in instrument revenue and approximately 200 basis points of overall company growth, beating the original placement target of around 4,500 units by nearly 40% as demand across independent and corporate practices exceeded internal forecasts.
CEO Jay Mazelsky stated on the Q4 2025 earnings call that “2025 was a defining year for our company,” citing scaled transformative innovations, expanded international commercial presence, and demonstrated resilience against broader economic uncertainty as the pillars of that assessment.
IDEXX enters 2026 guiding for $4.63B to $4.72B in revenue and $14.29 to $14.80 in EPS, with execution underpinned by a Cancer Dx panel expansion to include mast cell tumor detection at midyear, a controlled FNA (fine needle aspirate) rollout on inVue Dx, and continued international commercial scaling targeting a $45 billion-plus veterinary diagnostics TAM.
Also, in an April 8 research preview ahead of Q1 results, J.P. Morgan said it remains positive on IDEXX’s long-term outlook, specifically citing strong inVue Dx uptake and faster international growth as reasons to stay constructive despite near-term vet visit softness.
Wall Street’s Take on IDXX Stock
The 2025 placement record was not a one-time event — it was a balance sheet entry: every analyzer placed is a recurring consumable commitment locked into a clinic for the next decade.
Eleven analysts rate IDEXX laboratories stock a buy, five hold it, and none sell, with a median 12-month price target of $788 implying roughly 40% upside from current levels as consensus waits for vet visit trends to stabilize and the recurring revenue pull-through from record 2025 placements to compound through estimates.
The target spread runs wide enough to reflect a genuine debate: the bear anchors to a 2% annual U.S. clinical visit decline and slowing price realization, while the bull points to an aging pandemic-era pet cohort that is already showing green shoots in non-wellness visits for dogs aged five and older, a segment that skews 70% to 75% toward diagnostic-intensive care.
Priced at roughly 39x forward earnings against a normalized five-year P/E range that has rarely dipped below 45x, IDEXX laboratories stock appears undervalued relative to a business delivering double-digit EPS growth, expanding operating margins, and the fastest premium instrument ramp in company history.
The Cancer Dx panel, already generating meaningful reference lab pull-through, now reaches approximately 18% competitive submissions, meaning nearly one in five Cancer Dx orders comes from clinics that do not use IDEXX as their primary reference lab — a structural market share mechanism that resets the long-run revenue base well before it appears in near-term EPS.
If vet visit declines deepen beyond the 2% baseline already embedded in guidance, recurring revenue growth could fall to the low end of the 8% to 10% CAG Diagnostics range, compressing both the EPS trajectory and the multiple re-rating thesis.
Q1 2026 results on May 5 are the first real test: watch whether CAG Diagnostics recurring revenue lands within the guided 8.5% to 10.5% organic range as confirmation that inVue Dx pull-through is tracking and diagnostic frequency is holding.
What Does the Valuation Model Say?
The TIKR mid-case model assigns IDEXX a price target of around $919 per share by late 2030, embedding approximately 9% annual revenue growth and a net income margin expanding toward 26%, assumptions directly supported by the Cancer Dx panel expansion, inVue Dx FNA rollout, and international commercial scaling that management has already funded and initiated.
With IDEXX laboratories stock at $560.93 against a mid-case target of around $919, the roughly 64% potential total return over the next five years at an annualized rate of around 11% prices in none of the upside from FNA expansion, corporate account inVue penetration, or a recovery in wellness visits — making IDXX laboratories stock appear undervalued at forward multiples near decade lows for a business compounding EPS at double digits.
The question the model cannot resolve is whether the innovation cycle compounds faster than the vet visit headwind fades — and that tension is precisely what makes the risk-reward asymmetric.
What Has to Go Right
- CAG Diagnostics recurring revenue reaches the high end of the 8% to 10% organic guidance range, confirming that inVue Dx consumable pull-through is tracking to the guided $3,500 to $5,500 per-instrument annual run rate
- Cancer Dx mast cell tumor detection, launching at no additional cost at midyear in North America and rolling internationally across 2026, adds a high-volume panel and deepens the approximately $1.1 billion addressable canine oncology market
- FNA on inVue Dx exits controlled launch with strong uptake, extending the platform’s addressable use cases beyond the roughly 150 million manual cytology exams performed globally each year
- The aging pandemic-era pet cohort, with dogs 5 and older already showing modestly positive non-wellness visit growth, accelerates diagnostic intensity per visit beyond management’s conservative 2% annual visit decline baseline
What Could Go Wrong
- U.S. same-store clinical visits deteriorate beyond the planned 2% annual decline, particularly if macro pressure on lower-income households intensifies and wellness visit deferrals bleed into non-wellness categories
- Net price realization dips below the guided approximately 3.5% U.S. rate, compressing the revenue-per-visit contribution that has been buffering soft volume since 2023
- InVue Dx consumable pull-through tracks to the low end of the $3,500 to $5,500 range due to slower FNA adoption during the controlled launch phase, reducing the installed-base flywheel’s earning power
- The CEO transition from Jay Mazelsky to Michael Erickson introduces execution friction during a critical multi-platform scaling year, though management and outside analysts have characterized the handoff as a full-continuity event
Should You Invest in IDEXX Laboratories, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDXX stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX Laboratories, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IDXX stock on TIKR for Free →
